The natural history of moderate aortic stenosis in a veteran population

Poornima Yechoor, BA, Alvin S. Blaustein, MD, Faisal G. Bakaeen, MD, Lorraine D. Cornwell, MD, Joseph S. Coselli, MD, Scott A. LeMaire, MD, and Danny Chu, MD

Objective: Our objective was to evaluate the natural history of moderate aortic stenosis in veterans—a unique patient population with significant comorbidities.

Methods: We retrospectively reviewed the records of all patients who underwent echocardiography at a single veterans affairs hospital during 2006. We identified consecutive patients who had moderate aortic stenosis as indicated by a mean transaortic gradient of 25 to 40 mm Hg, peak aortic jet velocity of 3 to 4 m/s, or aortic valve area of 1.0 to 1.5 cm². The primary end point was defined as survival without aortic valve replacement.

Results: Of the 104 patients (mean age, 74 ± 10 years), 49% had diabetes, 21% had peripheral vascular disease, 21% were current smokers, 18% had chronic obstructive pulmonary disease, 60% had coronary artery disease, 89% had hypertension, and 31% had a body mass index of 30 kg/m² or more. Mean ejection fraction was 49% ± 12%. During the mean follow-up period of 22 months (range, 1-67 months), 30% of patients underwent aortic valve replacement—26% for symptomatic severe aortic stenosis and 4% concomitantly with coronary artery bypass grafting as the primary indicated operation—and 61% died. Event-free survivals were 48%, 24%, and 15% at 1, 3, and 5 years, respectively.

Conclusions: Our cohort of military veteran patients had significant comorbidities. Event-free survival for such patients who have moderate aortic stenosis is significantly lower than previously reported data suggest. Within this unique group of patients, identifying factors that accelerate the progression of moderate aortic stenosis would help surgeons select patients who may benefit from early aortic valve replacement for moderate aortic stenosis. (J Thorac Cardiovasc Surg 2013;145:1550-3)
The aim of our study was to follow a cohort of military veterans with moderate AS to better understand the natural history and impact of this disease in this unique group of patients.

PATIENTS AND METHODS

Patient Population

The study was granted waiver of consent and approved by the Institutional Review Boards at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) and Baylor College of Medicine, Houston, Tex. We retrospectively reviewed the medical records of all patients who underwent Doppler echocardiography at the MEDVAMC from January 1, 2006, to December 31, 2006. Patients with moderate AS were identified from the echocardiographic database maintained by the Division of Cardiology. For the purpose of our study, we defined moderate AS according to the current American College of Cardiology/American Heart Association valvular heart disease guidelines: a peak aortic jet velocity of 3.0 to 4.0 m/s, a mean transaortic valve pressure gradient of 25 to 40 mm Hg, or an aortic valve area of 1.0 to 1.5 cm². We excluded patients who had previous AVR, incomplete echocardiographic data, or incomplete follow-up data.

We identified a total of 104 consecutive patients who met our prespecified criteria and conducted a detailed chart review, using the MEDVAMC Computerized Patient Record System, to extract pertinent demographic, echocardiographic, clinical, surgical, and follow-up data for each patient (Table 1). The presence of diabetes mellitus, hypertension, CAD, chronic obstructive pulmonary disease, and peripheral vascular disease as documented in the patients’ charts was recorded. The degree of aortic valve calcification was not consistently documented in the echocardiographic reports reviewed and was thus not included in our study.

Follow-up

Follow-up data were available on the Computerized Patient Record System for all patients, and follow-up began from the date of the first echocardiogram that indicated moderate AS. The primary end point of our study was event-free survival, which was defined as freedom from death (from any cause) and AVR until the end of the follow-up period in August 2011.

Statistical Analysis

Continuous variables were expressed as mean ± standard deviation. Probabilities of event-free survival at 1, 3, and 5 years were obtained by Kaplan-Meier estimates (STATA version 11; StataCorp LP, College Station, Tex).

RESULTS

Event-Free Survival

During the mean follow-up period of 22 months (range, 1-67 months), 89 patients died (n = 58), underwent AVR (n = 26), or underwent AVR and then died during the follow-up period (n = 5). Estimated event-free survival was 48% at 1 year, 24% at 3 years, and 15% at 5 years (Figure 1).

Aortic Valve Replacement

Among the 31 patients who underwent AVR, severe symptomatic AS was the primary surgical indication in 27; the remaining 4 patients underwent AVR concomitantly with coronary artery bypass grafting because CAD was the primary indication for surgery. Of the 27 patients who had operations primarily for AVR, 15 had isolated AVR and 12 had concomitant coronary artery bypass grafting.

Death

Sixty-three patients died (from any cause) during the study period: 58 of the deaths were considered primary events and, as stated earlier, 5 deaths occurred after the patients underwent AVR. The available data did not allow us to record specific causes of death or whether deaths were of cardiac origin.

Patients With No Events

Of the 15 (14%) patients in whom no events were observed, 3 had progressed to severe AS and 12 still had moderate AS at the end of the follow-up period. At that time, 10 of these patients were recommended for monitoring with surveillance echocardiography because of a lack of symptoms or disease progression. Two of the 15 patients were deemed not to be surgical candidates, 2 were recommended for AVR but wanted more time to decide, and 1 patient declined any further workup or intervention for his AS.

DISCUSSION

The current standard of care for severe symptomatic AS is AVR, because the existing data suggest that, otherwise, patients have an average survival of only 2 to 3 years after the onset of symptoms, and they have a high risk of sudden death. Current guidelines for the management of moderate AS recommend clinical follow-up yearly and echocardiography every 1 to 2 years. However, the results of our present study suggest that moderate AS may not be as benign as previously reported and that current practice guidelines may be inadequate, especially for the military veteran population.

Previous studies of the natural history of moderate AS have produced conflicting results. Specifically, Horstkotte and Loogen reported an average interval of 13.4 years from diagnosis to aortic valve surgery, and Turina’s group reported 100% and 80% survivals at 1 and 4 years after diagnosis, respectively. However, in a small study, Kennedy and colleagues found that 14 of 66 patients died of causes attributed to moderate AS within 35 months after diagnosis. In addition, Otto’s group showed that event-free survival
at 2 years was 66%. Most recently, Rosenhek and associates\textsuperscript{13} reported 75% and 60% event-free survivals at 3 and 5 years, respectively. The same group also reported that patients with mild or moderate AS had an overall mortality that was 80% greater than that of age- and gender-matched controls.

Our results suggest that not only is the natural history of moderate AS in this veteran population not benign, but the event-free survival is significantly lower than even what Otto’s\textsuperscript{12} and Rosenhek’s groups\textsuperscript{13} had previously described. Eighty-five percent of patients had an event within our mean follow-up period of 22 months, and 61% of our patients died by the conclusion of our study, thus indicating that mortality in patients with moderate AS is not insignificant.

The body of literature on moderate AS also states that the rate of disease progression varies significantly among affected individuals.\textsuperscript{12,20} Some studies have attempted to identify risk factors for more rapid progression.\textsuperscript{1,12-15,19,21} For example, studies have shown that severe disease develops more rapidly in patients with senile calcific stenosis than in those with rheumatic or congenital AS.\textsuperscript{15,19} Other factors that have been associated with the rapid progression of AS include advanced age, concomitant CAD, and moderate to severe aortic valve calcification.\textsuperscript{13,15,19,21} Given that calcific AS is associated with aging, the association between advanced age and more rapid progression is not surprising. Similarly, with respect to its association with CAD, calcific AS was previously understood to be a degenerative disease, but more recent studies suggest that the pathophysiology of calcific stenosis is in fact similar to that of atherosclerosis.\textsuperscript{22,23} Thus, patients who have both AS and CAD probably have more severe aortic valve calcification than patients with AS alone. Finally, multiple studies have associated increased mortality with any degree of dystrophic calcification in either the aortic valve or the aorta.\textsuperscript{24,25} In our cohort of veterans, patients tended to be older (average age, 74 years) and to have significant comorbidities. Of note, 60% of our patients had concomitant CAD.

As our population ages and health care costs continue to rise, the prevalence of AS will continue to increase, as well. Additionally, because the MEDVAMC provides cardiac care to veterans in a large geographic area (including southern Texas, Louisiana, Oklahoma, Arkansas, Mississippi, and western Florida), many of the military veterans who are seen at our facility have to travel great distances. Therefore, to aggressively follow up every patient with moderate AS documented by echocardiography may be logistically difficult. However, given that even within 1 year, event-free survival is remarkably lower in this population than in other studied populations and that all-cause mortality in this group is high, we need to determine whether there is a subset of patients with moderate AS and a high risk of rapid disease progression who need to be followed up more closely than current guidelines indicate. The current literature suggests that more attention must be paid to patients with concomitant CAD and that the severity of aortic valve calcification should be recognized as an important predictor of outcome. Studying patients with these characteristics and identifying any other pertinent predictors unique to the veteran population will be an important next step, and modifying the existing guidelines for more vulnerable patients and involving both cardiologists and cardiac surgeons early on in these cases will allow the management of moderate AS to be tailored to individual patients’ needs.

Our study is subject to the limitations inherent in a retrospective review. Because our patient cohort was limited to military veterans, nearly all of our patients were men. Consequently, we cannot generalize our results to female patients.

**TABLE 1. Patient characteristics (N = 104)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>74 ± 10</td>
</tr>
<tr>
<td>Gender (male)</td>
<td>103 (99%)</td>
</tr>
<tr>
<td>Body mass index &gt; 30 kg/m(^2)</td>
<td>32 (31%)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>22 (21%)</td>
</tr>
<tr>
<td>Tobacco smoking history</td>
<td>66 (63%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>51 (49%)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>62 (60%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>93 (89%)</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>19 (18%)</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>22 (21%)</td>
</tr>
<tr>
<td>Mean ejection fraction (%)</td>
<td>49 ± 12</td>
</tr>
<tr>
<td>Peak aortic jet velocity (m/s)</td>
<td>3.2 ± 0.6</td>
</tr>
<tr>
<td>Mean transaortic valve gradient (mm Hg)</td>
<td>25.2 ± 9.7</td>
</tr>
<tr>
<td>Aortic valve area (cm(^2))</td>
<td>1.1 ± 0.3</td>
</tr>
</tbody>
</table>

Data are presented as number (percentage) or as mean ± standard deviation.

**FIGURE 1.** Kaplan-Meier event-free survival (events: aortic valve replacement, n = 31; death, n = 58).
patients. Also, whereas we carefully reviewed each echocardiographic report to verify the severity of each patient’s AS, we did not view the actual echocardiographic images to verify the measurements. Thus, the parameters used in our analyses were dependent on the image quality of the echocardiogram and on the judgment of the interpreting cardiologist. Additionally, the concomitant presence of symptoms of interest, including angina, syncope, and dyspnea, could not be determined for our patients at the time of each echocardiographic examination because of inconsistencies within their medical records.

CONCLUSIONS

Our study is significant not only because it corroborates emerging evidence that moderate AS is not a benign condition, but also because it focuses on the unique population of military veterans, who have significant comorbidities and risk factors. We found that moderate AS in this population is associated with rapid progression and considerable mortality. Therefore, the current practice guidelines for the management of moderate AS may not be appropriate for this group of patients. Further study of other prognostic factors unique to the veteran population is needed to improve our ability to assess and manage this disease in an individualized manner.

Stephen N. Palmer, PhD, ELS, contributed to the editing of the manuscript.

References


